Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GRN | P28799 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | CCNK | O75909 | 4/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13514043 | 0.87 | LMNA (0.50) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL4183301 | 0.84 | LMNA (0.48) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL951325 | 0.83 | LMNA (0.53) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL30046017 | 0.83 | LMNA (0.56) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL14638384 | 0.83 | LMNA (0.56) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL29691288 | 0.83 | LMNA (0.53) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL17159482 | 0.83 | LMNA (0.53) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL18338880 | 0.83 | LMNA (0.53) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL1599534 | 0.83 | LMNA (0.56) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL10130636 | 0.83 | LMNA (0.49) | LMNAKMT2AGRNSORT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| WO-2016161003-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHAMRACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| EP-2734516-B1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INT (DE) | 2015-06-17 | — | — | EP | disclosed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20080242865-A1 | PROCESSES FOR THE PREPARATION OF HYDROXYLAMINES | TANG DATONG | 2008-10-02 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080086007-A1 | 2-(Pyrazole-1-Yl)Pyridine Derivative | SHIONOGI & CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007044927-A2 | 6, 11-BRIDGED TRICYCLIC MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | LMNA 4270/4885KMT2A 1162/4885GRN 3857/4885 |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | LMNA 2540/4885KMT2A 1128/4885GRN 2773/4885 |
| US-20080086007-A1 | 2-(Pyrazole-1-Yl)Pyridine Derivative | MRPL21, CYP1A2, PDXK | LMNA 2987/4885KMT2A 3012/4885GRN 4258/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | LMNA 3616/4885KMT2A 3679/4885GRN 2969/4885 |
| US-20080242865-A1 | PROCESSES FOR THE PREPARATION OF HYDROXYLAMINES | CYP2B6, CYP2D6, CYP3A5 | LMNA 1379/4885KMT2A 2377/4885GRN 1506/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | LMNA 3009/4885KMT2A 3455/4885GRN 2397/4885 |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LMNA 750/4885KMT2A 1323/4885GRN 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.